Regenerex Biopharam receives first ophthalmic wound-healing patent in China

Co announces that it has received official notice from Chinese Patent Office that CSIPO intends to grant a patent for reversing or inhibiting eye degeneration associated with dry eye syndrome, as well as certain surgical eye procedures, including LASIK and P.R.K., with TB4, analogues, and derivatives. The patent claims are based on a significant body of data supporting the use of TB4 for wound healing of the cornea and other areas in and around the eye.